Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC

WCLC 2024

7 - 10 Sep 2024

Published: 26 Sep 2024

Views: 3

Rating:

Save

Dr Marina Garassino - University of Chicago, Chicago, USA

Dr Marina Garassino speaks to ecancer about the TROPION-Lung 01 study presented at WCLC 2024.

The latest data from this study indicates that measuring TROP2 expression using quantitative continuous scoring can help predict clinical outcomes for patients with advanced or metastatic non-small cell lung cancer who are being treated with the TROP2 antibody-drug conjugate datopotamab deruxtecan.

The data revealed that patients testing positive for TROP2 showed better response to datopotamab deruxtecan compared to those receiving docetaxel in the TROPION-Lung01 phase III trial.

Read the full story here.

Related Videos

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic...

Innovative treatments for solid tumours – TTFields as a therapeutic modality ( Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

More from ecancer